$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021485 Filed on November 03, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$98.82M	$96.13M	$85.74M
YoY Change	15.26%	11.36%	-2.46%
Cost Of Revenue	$1.354M	$1.275M	$1.250M
YoY Change	8.32%	4.85%	-13.19%
Gross Profit	$97.47M	$94.86M	$84.48M
YoY Change	15.37%	11.45%	-2.29%
Gross Profit Margin	98.63%	98.67%	98.54%
Selling, General & Admin	$32.28M	$30.53M	$25.70M
YoY Change	25.62%	15.12%	-5.27%
% of Gross Profit	33.12%	32.19%	30.42%
Research & Development	$28.52M	$28.09M	$28.28M
YoY Change	0.85%	-17.06%	16.33%
% of Gross Profit	29.26%	29.61%	33.47%
Depreciation & Amortization	$289.0K	$269.0K	$100.0K
YoY Change	189.0%		-50.0%
% of Gross Profit	0.3%	0.28%	0.12%
Operating Expenses	$60.80M	$58.62M	$53.98M
YoY Change	12.64%	-2.93%	4.94%
Operating Profit	$36.66M	$36.23M	$30.50M
YoY Change	20.21%	46.58%	-12.9%
Interest Expense	$72.00K	$72.00K	$300.0K
YoY Change	-76.0%	-88.39%	-79.17%
% of Operating Profit	0.2%	0.2%	0.98%
Other Income/Expense, Net		$72.00K
YoY Change		-88.42%
Pretax Income	$36.74M	$36.30M	$30.81M
YoY Change	19.23%	43.26%	-15.5%
Income Tax	$4.683M	$5.800M	$4.810M
% Of Pretax Income	12.75%	15.98%	15.61%
Net Earnings	$32.05M	$30.47M	$25.99M
YoY Change	23.31%	40.91%	-11.53%
Net Earnings / Revenue	32.44%	31.7%	30.32%
Basic Earnings Per Share		$0.26	$0.22
Diluted Earnings Per Share	$262.0K	$0.24	$0.20
COMMON SHARES
Basic Shares Outstanding	115.5M shares	115.8M shares	116.2M shares
Diluted Shares Outstanding		125.1M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$223.5M	$361.3M	$440.7M
YoY Change	-49.28%	-15.73%	59.69%
Cash & Equivalents	$77.62M	$94.69M	$76.19M
Short-Term Investments	$145.9M	$266.6M	$364.5M
Other Short-Term Assets	$10.32M	$9.067M	$6.700M
YoY Change	53.96%	14.77%	11.67%
Inventory	$4.988M	$4.994M	$4.910M
Prepaid Expenses
Receivables	$27.63M	$26.51M	$26.20M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$266.5M	$401.9M	$478.5M
YoY Change	-44.31%	-13.29%	55.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.002M	$1.226M	$1.675M
YoY Change	-40.18%	-6.48%	59.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$112.3M	$133.8M	$36.20M
YoY Change	210.16%	769.12%	-8.12%
Other Assets	$3.083M	$4.106M	$5.000M
YoY Change	-38.34%	-18.04%	45.01%
Total Long-Term Assets	$157.3M	$183.5M	$93.23M
YoY Change	68.72%	159.8%	-11.17%
TOTAL ASSETS
Total Short-Term Assets	$266.5M	$401.9M	$478.5M
Total Long-Term Assets	$157.3M	$183.5M	$93.23M
Total Assets	$423.8M	$585.4M	$571.7M
YoY Change	-25.88%	9.6%	38.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.908M	$6.558M	$10.55M
YoY Change	-34.55%	0.74%	40.03%
Accrued Expenses	$27.67M	$24.31M	$21.19M
YoY Change	30.58%	28.13%	-8.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$47.54M	$44.76M	$47.49M
YoY Change	0.1%	3.97%	22.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$409.0K	$413.0K	$900.0K
YoY Change	-54.56%	-70.5%	-60.87%
Total Long-Term Liabilities	$409.0K	$413.0K	$900.0K
YoY Change	-54.56%	-70.5%	-60.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.54M	$44.76M	$47.49M
Total Long-Term Liabilities	$409.0K	$413.0K	$900.0K
Total Liabilities	$47.95M	$45.17M	$48.39M
YoY Change	-0.92%	1.63%	17.66%
SHAREHOLDERS EQUITY
Retained Earnings	$195.0M	$162.9M	$82.46M
YoY Change	136.45%	188.54%	-450.06%
Common Stock	$591.5M	$571.5M	$516.3M
YoY Change	14.57%	15.08%	12.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares		10.90M shares	5.300M shares
Shareholders Equity	$375.8M	$540.2M	$523.3M
YoY Change
Total Liabilities & Shareholders Equity	$423.8M	$585.4M	$571.7M
YoY Change	-25.88%	9.6%	38.66%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	$32.05M	$30.47M	$25.99M
YoY Change	23.31%	40.91%	-11.53%
Depreciation, Depletion And Amortization	$289.0K	$269.0K	$100.0K
YoY Change	189.0%		-50.0%
Cash From Operating Activities	$49.43M	$48.70M	$35.10M
YoY Change	40.82%	60.21%	-27.48%
INVESTING ACTIVITIES
Capital Expenditures	-$65.00K	-$159.0K	-$400.0K
YoY Change	-83.75%	-77.29%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$140.5M	-$25.64M	$11.70M
YoY Change	1101.16%	-59.68%	-118.93%
Cash From Investing Activities	$140.5M	-$25.80M	$11.20M
YoY Change	1154.21%	-59.87%	-118.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-207.0M	-23.64M	-700.0K
YoY Change	29467.0%	-500.73%	600.0%
NET CHANGE
Cash From Operating Activities	49.43M	48.70M	35.10M
Cash From Investing Activities	140.5M	-25.80M	11.20M
Cash From Financing Activities	-207.0M	-23.64M	-700.0K
Net Change In Cash	-17.07M	-742.0K	45.60M
YoY Change	-137.44%	-97.35%	-432.85%
FREE CASH FLOW
Cash From Operating Activities	$49.43M	$48.70M	$35.10M
Capital Expenditures	-$65.00K	-$159.0K	-$400.0K
Free Cash Flow	$49.49M	$48.86M	$35.50M
YoY Change	39.41%	57.12%	-26.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001088856
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50679
	dei	Entity Registrant Name EntityRegistrantName	CORCEPT THERAPEUTICS INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0487658
	dei	Entity Address Address Line1 EntityAddressAddressLine1	149 Commonwealth Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	327-3270
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CORT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	115451895	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94688000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76190000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	266643000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	364506000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26508000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26198000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	4994000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4910000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9067000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6697000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	401900000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	478501000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	13659000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	16247000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1022000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2509000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1226000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1675000	USD
CY2021Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	133845000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	36196000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4106000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000	USD
CY2021Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	29641000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	31603000	USD
CY2021Q3	us-gaap	Assets Assets	585399000	USD
CY2020Q4	us-gaap	Assets Assets	571731000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6558000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10554000	USD
CY2021Q3	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	12844000	USD
CY2020Q4	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13704000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24309000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21186000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1046000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2050000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	44757000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47494000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	501000	USD
CY2021Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	413000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	398000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	45170000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	48393000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	122000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	571377000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	516140000	USD
CY2021Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	194304000	USD
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	75795000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	115000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	415000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	162915000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	82456000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	540229000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	523338000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	585399000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	571731000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	96131000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86327000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	267156000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	268139000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1275000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1216000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3927000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4328000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	61608000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	179343000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	170447000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28091000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33869000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85345000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86489000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30533000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26523000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90071000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79630000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	59899000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	36232000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	24719000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	87813000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	97692000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5833000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3716000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	622000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	457000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3103000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36304000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	25341000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	88270000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	100795000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7811000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20778000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	30471000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	21625000	USD
	us-gaap	Net Income Loss NetIncomeLoss	80459000	USD
	us-gaap	Net Income Loss NetIncomeLoss	80017000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	8000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	109000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	85000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-265000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	259000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-77000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-81000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-23000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-347000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	84000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-35000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	57000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	30371000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21362000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	80159000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	80333000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.65
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115791000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115734000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116297000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115107000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125136000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124464000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127173000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123337000	shares
	us-gaap	Profit Loss ProfitLoss	80459000	USD
	us-gaap	Profit Loss ProfitLoss	80017000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32121000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	25109000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2047000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	11778000	USD
	cort	Accretion Expense Income AccretionExpenseIncome	3805000	USD
	cort	Accretion Expense Income AccretionExpenseIncome	404000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	783000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	447000	USD
	cort	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1487000	USD
	cort	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1228000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-148000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	310000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2029000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2655000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-694000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2288000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1882000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-894000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1562000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3961000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-988000	USD
	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	-860000	USD
	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	9055000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3138000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-4315000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1505000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1205000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	118465000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	116899000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	404000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	807000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	308864000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	193418000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	312805000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	323094000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4345000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-130483000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13182000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13240000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88485000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	275000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	20319000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	90000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-95622000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12875000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18498000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-709000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76190000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31269000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94688000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30560000	USD
	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	9705000	USD
	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	900000	USD
	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	0	USD
	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	775000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	371182000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	480000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	275000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7988000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	49000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	30065000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	409489000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7639000	USD
CY2020Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	835000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8548000	USD
CY2020Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	530000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	28327000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	453698000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6020000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-166000	USD
CY2020Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	155000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8755000	USD
CY2020Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-263000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	21625000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	489680000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	523338000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10083000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33540000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22520000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10142000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	510802000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6661000	USD
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	29170000	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3238000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11131000	USD
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-34000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	26523000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	522675000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6225000	USD
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	25775000	USD
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4266000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10999000	USD
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-100000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	30471000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	540229000	USD
	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
CY2021Q3	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	0	USD
CY2020Q4	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	1685000	USD
CY2021Q3	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	13727000	USD
CY2020Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	12916000	USD
CY2021Q3	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	4926000	USD
CY2020Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	6556000	USD
CY2021Q3	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	18653000	USD
CY2020Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	21157000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	13659000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	16247000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	4994000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4910000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3862000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3528000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2636000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1853000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1226000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1675000	USD
CY2021Q3	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11146000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10474000	USD
CY2020Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	9412000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10144000	USD
CY2021Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	871000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	665000	USD
CY2021Q3	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	756000	USD
CY2020Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	612000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	544000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	151000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	518000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	202000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24309000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21186000	USD
CY2021Q3	cort	Deposits For Clinical Trials DepositsForClinicalTrials	3900000	USD
CY2020Q4	cort	Deposits For Clinical Trials DepositsForClinicalTrials	4800000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	473668000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	451226000	USD
CY2021Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	1400000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1300000	USD
	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P2Y
	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P8M
CY2021Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	cort	Number Of Stock Option Plans NumberOfStockOptionPlans	2	stockOptionPlan
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	20300000	USD
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	4300000	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	600000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1700000	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	22.69
	cort	Treasury Stock Value Acquired Cost Method Net TreasuryStockValueAcquiredCostMethodNet	98200000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	900000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3600000	shares
CY2021Q3	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	200000	shares
	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	1200000	shares
CY2021Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2300000	USD
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	10900000	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5300000	shares
CY2021Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	47000	USD
CY2020Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	53000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	151000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	182000	USD
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10999000	USD
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	8755000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	32272000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	25291000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	30471000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	21625000	USD
	us-gaap	Net Income Loss NetIncomeLoss	80459000	USD
	us-gaap	Net Income Loss NetIncomeLoss	80017000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115791000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115734000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116297000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115107000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9345000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8730000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10876000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8230000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125136000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124464000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127173000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123337000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.65
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	25500000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26000000	shares
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5800000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7800000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3700000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20800000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	600000	USD
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1400000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7200000	USD
CY2021Q3	cort	Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance	1800000	USD

Files In Submission

Name	View Source	Status
0001628280-21-021485-index-headers.html	Edgar Link	pending
0001628280-21-021485-index.html	Edgar Link	pending
0001628280-21-021485.txt	Edgar Link	pending
0001628280-21-021485-xbrl.zip	Edgar Link	pending
cort-20210930.htm	Edgar Link	pending
cort-20210930.xsd	Edgar Link	pending
cort-20210930_cal.xml	Edgar Link	unprocessable
cort-20210930_def.xml	Edgar Link	unprocessable
cort-20210930_htm.xml	Edgar Link	completed
cort-20210930_lab.xml	Edgar Link	unprocessable
cort-20210930_pre.xml	Edgar Link	unprocessable
cort93021ex311.htm	Edgar Link	pending
cort93021ex312.htm	Edgar Link	pending
cort93021ex321.htm	Edgar Link	pending
cort93021ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2021 Q4 Form 10-Q Financial Statement

#000162828021021485 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2021 Q4 Form 10-Q Financial Statement

#000162828021021485 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort